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Background: Improving our understanding of the relationship between the genotype and the drug resistance
phenotype of Mycobacterium tuberculosis will aid the development of more accurate molecular diagnostics for
drug-resistant tuberculosis. Studies that use direct genetic manipulation to identify the mutations that cause
M. tuberculosis drug resistance are superior to associational studies in elucidating an individual mutation’s contri-
bution to the drug resistance phenotype.
Methods:We systematically reviewed the literature for publications reporting allelic exchange experiments in any
of the resistance-associated M. tuberculosis genes. We included studies that introduced single point mutations
using specialized linkage transduction or site-directed/in vitro mutagenesis and documented a change in the
resistance phenotype.
Results:We summarize evidence supporting the causal relationship of 54 different mutations in eight genes (katG,
inhA, kasA, embB, embC, rpoB, gyrAand gyrB) and one intergenic region (furA-katG) with resistance to isoniazid, the
rifamycins, ethambutol and fluoroquinolones. We observed a significant role for the strain genomic background in
modulating the resistance phenotype of 21 of these mutations and found examples of where the same drug
resistance mutations caused varying levels of resistance to different members of the same drug class.
Conclusions: This systematic review highlights those mutations that have been shown to causally change pheno-
typic resistance in M. tuberculosis and brings attention to a notable lack of allelic exchange data for several of the
genes known to be associated with drug resistance.
Keywords: M. tuberculosis, microbial susceptibility tests, genetics, SNPs, in vitro resistance
Introduction
The 2012 WHO report on global tuberculosis (TB) surveillance sug-
gests that only one in five patients with drug-resistant TB are diag-
nosed and appropriately treated.1 Patients with undiagnosed drug
resistance have higher morbidity and mortality than patients with
drug-susceptible disease, and may continue to spread drug-
resistant TB in their communities.2 The WHO has stated that a
major challenge for drug-resistant TB control is the lack of laboratory
capacity to diagnose resistance.1 Newer, molecular-based diagnos-
ticsdetectmutationsconferringdrugresistanceandofferadvantages
for the identificationof resistance inMycobacteriumtuberculosis (Mtb)
over traditional culture-based techniques, including a more rapid
turnaround time and a lower level of skill required to run the
tests.3 – 5 A thorough understanding of which mutations encode
drug resistance in Mtb will be helpful in focusing research aimed
at elucidating the underlying mechanisms of resistance and in sup-
porting the development of more accurate molecular diagnostic
tests for patient care.
Epidemiological studies of Mtb drug resistance have largely
focused on the association of specific mutations with the drug
resistance phenotype, primarily through the comparison of
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mutations in specific genes in resistant clinical strains with drug-
susceptible counterparts.6 – 8 This approach, however, cannot de-
finitively establish causality between the mutation and the
resistance phenotype. Studies using direct bacterial genetic ma-
nipulation to identify the mutations that cause Mtb drug resistance
can better elucidate the individual mutation’s contribution to
the drug resistance phenotype and uncover whether additional
factors, likesynergy, strain background or interactions betweenmuta-
tions, modulate this relationship. The purpose of this systematic
review is to clarify mutation–phenotype relationships in Mtb by iden-
tifying which mutations have been causally linked to Mtb drug resist-
ance and in what context these causal observations have been made.
Methods
Definitions
Two types of mutation were included in this study: (i) non-synonymous nu-
cleotide substitutions, denoted by x#y, where x represents the wild-type
amino acid, # the codon number and y the variant amino acid; and (ii) non-
coding (ribosomal RNA, promoter, intergenic regions) nucleotide substitutions,
denoted by #xy, where # refers to the position relative to the start of the non-
coding region, x is the wild-type nucleotide base and y is the variant nucleotide
base. For phenotype measurements, we defined MIC as the lowest concentra-
tion of drug that inhibits bacterial growth and IC50 as the concentration of drug
required to inhibit supercoiling activity by 50%. We describe a mutation leading
to any increase in MIC as causative of resistance; mutations that increase the
MIC above the accepted critical concentration for medical diagnostic testing
is said to be causing clinical levels of resistance.9
Literature search
Using the search strategy described in Table 1, we identified peer-reviewed
primary research studies that reported the effect of creating specific muta-
tions in resistance-associated genes on the drug resistance phenotypes of
Mtb strains. We searched the PubMed and EMBASEdatabases from January
1980 to June 2012, using combinations of the keywords listed in Table 1.
Bibliographies of articles selected for further review were hand-searched
and additional references not previously identified were added as appropri-
ate. We performed full-text mining of keywords in search theme 4 ‘Intro-
duction of mutation’ on articles retrieved by PubMed and EMBASE using
search themes 1–3. This additional step was undertaken to capture articles
that did not have these keywords in the title or abstract.
Study selection criteria
Methods to investigate phenotype causation have included (i) gene knock-
outs and complementation of the resulting null mutants; (ii) increasing
transcription of the gene, leading to its overexpression; and (iii) invitro selec-
tion of drug-resistant clones by plating susceptible strains on serial dilutions
of a drug.10 – 12 While the former methods shed light on whether the entire
gene is essential for resistance, spontaneous mutants with a resistance
phenotype may include compensatory mutations. Allelic exchange techni-
ques, which introduce specific point mutations into a gene of interest, do
not have these limitations and directly define the causative role for muta-
tions in drug resistance, making it our method of choice for this review.
We included studies if they met the following criteria: (i) single point
mutations within a putative resistance gene were introduced into
Mtb strains using specialized linkage transduction or site-directed/in vitro
mutagenesis; and (ii) a change in the resistance phenotype was documen-
ted. The resistance phenotypes were reported as MIC measurements
or IC50 results performed before and after the introduction of a
mutation. Researchers have demonstrated a quinolone structure–activity
relationship for the gyrA/B protein complex, in which inhibition of supercoil-
ing activity by 50% (IC50) correlates well (better than DNA cleavage) with
inhibition of Mtb growth by the fluoroquinolones (FQs).13 We included
studies that used liquid- or solid-based media for drug susceptibility testing.
We excluded manuscripts that (i) studied mycobacterial species other
than Mtb; (ii) created knockout or overexpression of a gene instead of a
single point mutation; (iii) did not specify the host strain used when meas-
uring the MIC effect; (iv) did not state how the unique transfer of the
intended point mutation was confirmed; or (v) did not have a phenotypic
result (MIC or IC50). We excluded in vitro selected mutations in order to
remove the potential effects of compensatory mutations.
Data extraction
For every study that met our eligibility criteria, two of three authors (H. N.-G.,
K. R. J. and M. R. F.) independently reviewed the data and one additional
author (M. B. M.) adjudicated differences between the authors. From each
publication, the following information was extracted by two authors
(H. N.-G. and K. R. J.): authors; publication year; gene; amino acid and nu-
cleotide coordinates of the mutation; host strain and method used to intro-
duce the mutation; method used to confirm introduction of the mutation;
resistance genotypic and phenotypic susceptibility methods; and pheno-
typic results. Additional details and clarifications were obtained via
personal correspondence by one of the authors (H. N.-G.).
Results
Of the 489 publications that we identified, 444 were excluded after
abstract review. We performed full-text reviews of the remaining
45 papers and excluded a further 25. We identified 433 more
papers through an additional text-mining step. Seventeen of these
were selected through title and abstract review, but 16 were excluded
upon full-text review. In total, 21 articles were selected for inclusion
and final data extraction (Figure 1).
Isoniazid
We identified studies examining 11 different putative isoniazid re-
sistance mutations in four Mtb genes: katG, the furA-katG intergenic
region, inhA and kasA. Of these 11 mutations, 7 were shown to
confer resistance to isoniazid (Table 2). No two studies looked at the
same point mutation.
Mutations that caused isoniazid resistance
Pym et al.14 investigated two point mutations in katG using host
strain INH34, a clinical isolate with inherent up-regulation of
ahpC.15 The use of this strain ensured that any phenotypic differ-
ences detected among the INH34 transformants could not be
due to the emergence of compensatory mutations in the promoter
region of ahpC. Both katG S315Tand T275P caused isoniazid resist-
ance. Vilchezeetal.16 introduced mutation S94A into the inhAgene
of an H37Rv Mtb reference strain and found that it conferred a
.5-fold increase in resistance to both isoniazid and ethambutol.
Richardson et al.17 demonstrated that a katGW300G H37Rv trans-
formant caused a 1280-fold increase in isoniazid MIC, while Ando
et al.18 found that complementing mutations (27GA,210AC and
212GA) into a clinical isolate with a deleted furA-katG gene con-
ferred low-level isoniazid resistance (0.1–1 mg/L).
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Mutations that had no effect on isoniazid resistance
Pym et al.14 complemented a resistant furA-katG deletion Mtb
mutant with a katG gene carrying the A139V mutation and
found that it restored isoniazid susceptibility. This demonstrates
that A139V does not confer resistance in this strain. Vilcheze
et al.16 found that kasA G312S and F413L mutations in H37Rv
caused no detectable changes in isoniazid MIC. Ando et al.18
found that mutation C41T in furA resulted in no appreciable
change in MIC relative to the Mtb strain harbouring the wild-type
furA gene (Table 3).
Ethambutol
We identified six studies examining nine different putative etham-
butol resistance mutations in the gene embB. Four of these
Table 1. Search strategy to identify studies of mutations documented to confer resistance by evidence of genetic experiment
Search theme
1. organism 2. drug resistance 3. mutation
4. method of
introducing mutation
PubMed database
Medical Subject Headings
(MeSH) terms
1. ‘mycobacterium
tuberculosis’
1. ‘drug resistance’,
OR
1. ‘mutation’, OR NA
2. ‘microbial
sensitivity tests’
2. ‘amino acid
substitution’, OR
3. ‘mutagenesis,
site-directed’, OR
4. ‘codon’
text terms 1. ‘mycobacterium
tuberculosis’, OR
1. ‘resistance’, OR 1. ‘mutation*’, OR 1. ‘isogenic’, OR
2. ‘m tuberculosis’, OR 2. ‘mic’, OR 2. ‘mutagenesis’, OR 2. ‘engineered’, OR
3. ‘mtb’ 3. ‘inhibitory
concentration’, OR
3. ‘mutant*’, OR 3. ‘mutagenesis’, OR
4. ‘drug susceptibility’ 4. ‘nonsense’, OR 4. ‘recombinant’, OR
5. ‘missense’, OR 5. ‘site-directed’, OR
6. ‘frameshift’, OR 6. ‘allelic’, OR
7. ‘codon*’, OR 7. ‘transduction’, OR
8. ‘transduction’ 8. ‘wild-type’, OR
9. ‘induced’, OR
10. ‘introduced’
EMBASE
Emtree tool 1. ‘mycobacterium
tuberculosis’
1. ‘drug resistance’ 1. ‘mutation’, OR NA
2. ‘site-directed
mutagenesis’, OR
3. ‘amino acid
substitution’, OR
4. ‘codon’
text terms 1. ‘mycobacterium
tuberculosis’, OR
1. ‘resistance’, OR 1. ‘mutations*’ OR 1. ‘isogenic’, OR
2. ‘m tuberculosis’, OR 2. ‘mic’, OR 2. ‘mutagenesis’, OR 2. ‘engineered’, OR
3. ‘mtb’ 3. ‘mics’, OR 3. ‘mutant*’, OR 3. ‘mutagenesis’, OR
4. ‘inhibitory
concentration’, OR
4. ‘nonsense’, OR 4. ‘recombinant’, OR
5. ‘drug susceptibility’ 5. ‘missense’, OR 5. ‘site-directed’, OR
6. ‘dst’ 6. ‘frameshift’, OR 6. ‘allelic’, OR
7. ‘codon*’, OR 7. ‘linkage
transduction’, OR
8. ‘transduction’ 8. ‘wild-type’, OR
9. ‘induced’, OR
10. ‘introduced’
NA, not available.
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investigated the same three mutations [Met306Ile (ATA),
Met306Ile (ATC) and Met306Val]. We identified one additional
study that examined five putative ethambutol resistance muta-
tions in embC. All nine embB mutations and one embC mutation
were shown to confer resistance to ethambutol.
Mutations that caused ethambutol resistance
Two different clinical strains were chosen by Safi et al.19 as host
backgrounds for introducing embB gene mutations into codon
306: drug-susceptible 210 belonging to the W-Beijing family, the
embB sequence of which is identical to that of laboratory strain
H37Rv; and the ethambutol-resistant clinical isolate 5310 that
had been reverted back to wild-type embB sequence. Mutations
M306V, M306L, M306I (ATA) and M306I (ATC) all caused etham-
butol resistance (MIC.4 mg/L) when incorporated into wild-type
strain 210 and strain 5310.19
Starkset al.20 introduced theembBM306Vallele into H37Rv and
Beijing F2, resulting in a 4-fold ethambutol MIC increase, while
M306I resulted in a 2-fold increase in both host strains. Plinke
et al.21 found a 4-fold increase in ethambutol MIC for mutations
M306V and M306I (ATA) and a 2-fold increase for mutation M306I
(ATC) when introduced into H37Rv. These, however, remained below
the critical clinical cut-off value. Goude et al.22 showed that mutation
M70I introducedintoH37Rvpresentedasmall increase inethambutol
MIC (4 mg/L), insufficient to render it clinically resistant.
Safi et al.23 also looked at the role of common mutations found
in clinical strains with high-level ethambutol resistance at the
embB 406 and 497 codons. They substituted the wild-type clinical
Mtb 210 strain embB G406 codon with G406A, G406D, G406C or
G406S, all of which led to ethambutol resistance. Replacing the
wild-type embB Q497 codon in strain 210 with the Q497R codon
also increased the ethambutol MIC (Table 2).
Mutations that potentiated susceptibility or had no effect
on ethambutol resistance
Goude et al.22 introduced a point mutation at the conserved aspar-
tate D294G that had previously been shown to affect the activity of
embC inMycobacteriumsmegmatis to determine whether a similar
effect would be seen in Mtb. They found that D294G and a further
two mutations introduced into codon 300 of the embC arabinosyl-
transferase (M300L and M300V) increased susceptibility to etham-
butol. Mutation M300I had no resistance effect (Table 3).
Rifamycins
We identified four studies that examined five putative single rifa-
mycin resistance mutations and three double mutations in Mtb.
The most common rifamycin amino acid substitutions in clinical
strains (rpoB codons 531, 526 or 516) and two additional muta-
tions were shown to individually confer resistance to rifamycins.23
Mutations that caused resistance to rifamycins
Williams et al.24 investigated the causal relationship between spe-
cific amino acid changes and three rifamycins (rifampicin, rifapen-
tine and rifabutin) by incorporating mutations D516V, H526Y and
S531L into the rpoB gene of Mtb H37Rv. Mutant alleles S531L and
H526Y conferred high-level resistance to the three rifamycins
Partially relevant articles identified and
screened for retrieval (n = 922)
Potentially eligible articles (n = 62)
No abstract available (n = 2)
Reviews (n = 68)
Commentaries (n = 1)
Association studies (n = 125)
Immunology studies (n = 40)
Mathematical model /
    computational biology (n = 12)
Diagnostics (n = 173)
Vaccine / drug development (n = 29)
Molecular / structural /
    biomedical studies  (n = 160)
New methodologies (n = 32)
Deletion / KO / overexpression (n = 40)
Other species (n = 169)
Other endpoint (n = 11)
Resistance selected in vitro (n = 14)
Viability/growth studies (n = 17)
Excluded based on title / abstract
(n = 860)
Excluded upon full text review
(n = 41)
Association studies (n = 3)
Other species (n = 12)
Deletion / KO /
   overexpression (n = 7)
Host strain not specified (n = 1)
No method for confirming
   introduction of mutation (n = 2)
Other endpoints (n = 12)
DST / MICs not performed in
   standard / uniform way (n = 1)
Resistance selected in vitro (n = 3)
Eligible meta-analysis (n = 21)
Note: Papers may have been excluded on one or more
exclusion criteria.
Figure 1. Study selection process and reasons for exclusion of studies. KO,
knock-out.
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Table 2. Mutations shown to confer resistance to isoniazid, ethambutol or RIF
Drug Gene Host strain Substitution MIC (mg/L) Reference
Isoniazid katG INH34a WTb 0.1 Pym et al., 200214
S315T 5
T275P .10
H37Rv WT 0.1 Richardson et al., 200917
W300G 128
furA-katG intergenic
region
NCGM2836c WTb 0.1 Ando et al., 201118
G7A 0.4
A10C 0.4
G12A 0.15
inhA H37Rv WT 0.1 Vilcheze et al., 200616
S94A 0.5
Ethambutol embB 210d WT 2 Safi et al., 201023
G406S 6
G406A 7
G406D 7
G406C 7
Q497R 12
210d WT 2 Safi et al., 200819
M306I (ATA) 7
M306I (ATC) 7
M306L 8.5
M306V 14
5310e WT 3
M306I (ATA) 16
M306I (ATC) 16
M306L 20
M306V 28
H37Rv WT 1 Plinke et al., 201121
M306I (ATC) 2
M306I (ATA) 4
M306V 4
H37Rv WT 5 Starks et al., 200920
M306V 20
M306I (ATA) 10
Beijing F2 WT 5
M306V 20
M306I (ATA) 10
embC H37Rv WT 3 Goude et al., 200922
T270I 4
Rifampicin rpoB H37Rv WT 0.25 Williams et al., 199824
D516V 32
H526Y 64
S531L .64
WT ≤0.015f
H526Y 16f
S531L 16f
WT 0.03g
D516V 16g
H526Y 16g
S531L .64g
H37Ra WT 1.5 Zaczek et al., 200926
D516V 50
H526Y 25
Continued
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(Table 2). Clones containing mutation D516V showed resistance to
rifampicin and rifapentine but susceptibility to rifabutin. Gill and
Garcia25 also found that these three mutant alleles led to elevation
of IC50 values for rifampicin, rifabutin and rifaximin. Theyfoundthat
the rifabutin IC50 was elevated less by mutations S531L and D516V
than by H526Y. Zaczeketal.26 explored whether the background Mtb
strain affected the change in the rifampicin MIC. All strain
backgrounds (H37Ra, KL1936 and KL463) containing rpoB genes
with mutations H526D, D516Vor S531L had high-level rifampicin re-
sistance.
Noting that 5% of clinical strains with rifampicin resistance do
not have mutations in the 81 bp region of rpoB, Siu et al.27 aimed
to identify mutations located outside this rifampicin resistance-
determining region. They found that H37Ra transformants
Table 2. Continued
Drug Gene Host strain Substitution MIC (mg/L) Reference
S531L 50
S512I+D516G 6.2
Q513L 6.2
M515I+D516Y 6.2
D516Y 3.1
KL1936h WT 1.5
H526D 50
D516V 25
Q513L 12.5
S531L 50
Q510H+D516Y 6.2
S512I+D516G 6.2
M515I+D516Y 6.2
D516Y 6.2
KL463i WT 1.5
H526D 50
D516V 25
Q513L 50
S531L 50
Q510H+D516Y 6.2
S512I+D516G 6.2
M515I+D516Y 6.2
D516Y 3.1
H37Raj WT 1.5
H526D 50
D516V 25
S531L 50
Q510H+D516Y 6.2
S512I+D516G 6.2
Q513L 6.2
M515I+D516Y 6.2
D516Y 6.2
H37Ra WT ,0.1 Siu et al., 201127
S531L 64
V146F 64
I572F 8–16
WT, wild-type.
aDfurA-DkatG clinical isolate resistant to isoniazid and with inherent up-regulation of ahpC.
bComplemented with the wild-type katG gene.
cDfurA-DkatG clinical isolate resistant to isoniazid.
dDrug-susceptible clinical strain, member of the W-Beijing family.
eClinical isolate resistant to ethambutol.
fRifabutin.
gRifapentine.
hRifampicin-susceptible clinical strain containing PrpoB natural promoter.
iRifampicin-susceptible clinical strain.
jContaining a modified heat shock promoter (Phsp65).
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containing mutations S531L or V146F were resistant to rifampicin.
Transformants containing mutation I572L had a rifampicin
MIC raised to 8–16 mg/L. Although V146F and I572L conferred
resistance, the authors noted that they are rarely seen in clinical
strains.
Zaczek et al.26 found that D516Y conferred low-level resistance
in strains KL453, KL1936 and H37Ra. The double mutations
Q510H+D516Y, S512I+D516G and M515I+D516Y all conferred
low-level resistance in these strains. Hence, the substitutions in
position 516 (D/Y; D/G), even when supported with Q510H, M515I
or S512I, did not result in a large increase in the rifampicin MIC.
The authors therefore concluded that a mutation D/Y or D/G at
516 is not sufficient to confer clinical rifampicin resistance in Mtb,
in contrast to D/V, which does confer clinical resistance.
Mutation(s) with an effect on resistance to rifamycins that
varied by host strain
Zaczek et al.26 found that mutation Q513L led to high-level rifam-
picin resistance in strain KL463, lower-level resistance in KL1936
and no significant increase in MIC in H37Ra (Table 2).
FQs
We identified nine articles that studied the causal relationship
between mutations in gyrA/B in Mtb and resistance to FQs. All
except one of these studies measured IC50 rather than MIC as
the resistance outcome. Not all FQs have the same effect on Mtb.
Ofloxacin and ciprofloxacin have bacteriostatic antimycobacterial
activity, whereas moxifloxacin shows high bactericidal activity.25
gyrA
Mutations that caused FQ resistance Onodera et al.28 found that
gyrA mutations A90V and A90V+D94V greatly increased the IC50
of levofloxacin and ciprofloxacin compared with the wild-type
(Table 4). Aubry et al.29 reported that gyrA mutations A90V, D94G
and D94H led to increased IC50s of four FQs; in addition, mutation
A90V+D94G had an additive effect as a double mutant. Matrat
et al.30 found that transformants bearing gyrA G88A and G88C
were more resistant than wild-type gyrase to inhibition by FQs.
The increases in IC50 for G88C were higher than for G88A with
respect to gatifloxacin, levofloxacin and moxifloxacin and similar
for ofloxacin. Malik et al.31 reported that the A74S mutation
increased the MIC 2-fold to 4-fold for each FQ tested, which is
slightly above the critical concentration. While the single D94G mu-
tation conferred resistance, the addition of A74S to D94G had a
synergistic effect, further increasing the MICs of all FQs tested by
2-fold to 8-fold over those for the single D94G mutation. Kim
et al.32 found that IC50 values of levofloxacin, ciprofloxacin and
gatifloxacin against DNA gyrase containing S95+D94G were
2-fold greater than those against DNA gyrase containing S95
with A74S+D94G, which was higher than the wild-type.
Mutations that increased susceptibility or had no effect on FQ
resistance Aubry et al.29 reported that gyrA mutations T80A and
T80A+A90G led to a reduced IC50; A90G alone did not affect the
FQ IC50 (Table S1, available as Supplementary data at JAC Online).
Malik et al.31 also found that the gyrA double mutation T80A+A90G
had no significant effect on MICs and actually decreased the MIC
for ofloxacin. Transformants with G247S and A384V, located outside
the gyrA quinolone resistance-determining region (QRDR), had
similar FQ MICs compared with negative controls.
Matrat et al.33 looked to identify the minimum number of muta-
tions needed to increase FQ susceptibility in Mtb to levels similar to
those in Escherichia coli. An A83S mutation in gyrA was sufficient
to decrease moxifloxacin IC50 to a susceptible range for E. coli. To
decrease the ofloxacin IC50 to a susceptible range similar to
E. coli, the A83S mutation had to be coupled with a second substi-
tution, either M74I in gyrA or R447K in gyrB. Modification of the
vicinity of A83 (residues 84 and 85) did not have any effect on FQ
susceptibility.
Kim et al.32 explored whether lineage-specific amino acid
residues affect FQ resistance. They conducted in vitro IC50
studies using recombinant DNA gyrase bearing an S95 residue
in gyrA. The wild-type (gyrA containing S95) and gyrA containing
A74S with the S95 demonstrated similar levels of in vitro FQ
susceptibility. The authors believed the reason that this muta-
tion did not show the higher FQ resistance described in previous
reports was because those earlier strains from China were
Table 3. Mutations shown not to confer resistance to isoniazid, ethambutol or rifampicin
Drug Gene Host strain Substitution MIC (mg/L) Reference
Isoniazid katG INH34a A139V 0.1 Pym et al., 200214
furA-katG intergenic region NCGM2836a C41T 0.1 Ando et al., 201118
kasA H37Rv G312S 0.1 Vilcheze et al., 200616
F413L 0.1
Ethambutol embC H37Rv M300L 0.5b Goude et al., 200922
M300I 3
M300V 0.5b
D294G 0.5b
Rifampicin rpoB H37Rv D516V ≤0.015c Williams et al., 199824
H37Ra Q510H+D516Y 1.5 Zaczek et al., 200926
aDfurA-DkatG clinical isolate resistant to isoniazid and with inherent up-regulation of ahpC.
bMutations shown to increase susceptibility to isoniazid, ethambutol or rifampicin.
cRifabutin.
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Table 4. Mutations shown to cause resistance to at least one FQ
Gene Host straina Substitution
Ofloxacin IC50 or
MICb (mg/L)
Ciprofloxacin IC50 or
MICc (mg/L)
Levofloxacin IC50 or
MICd (mg/L)
Gatifloxacin IC50 or
MIC (mg/L)
Moxifloxacin IC50 or
MICe (mg/L) Reference
gyrA — WT — 12.2 13.9 — — Onodera et al.,
200128A90V — .400 .400 — —
A90V+D94V — .400 .400 — —
— WT 10 — 12 2.5 2 Aubry et al.,
200629A90V 100 — 55 20 35
D94G 350 — 170 70 50
D94H 800 — 320 150 90
A90V+D94G .1600 — .1600 .320 .160
— WT 10 — 5 4 4 Matrat et al.,
200630G88A 40 — 30 7 10
G88C 50 — 100 .128 35
— WT (S95) — 18 34 9 — Kim et al.,
201232D94G+S95 — 196 310 76 —
A74S+D94G+S95 — 107 171 48 —
H37Rv or
Erdman
WT 0.5 ,0.25–0.5 ,0.25 — ,0.25 Malik et al.,
201231
H37Rv A74S+D94G 16–32 16 16 — 4–16
A90V 2–4 2–4 0.5–2 — 0.5–1
Erdman A74S 1–2 1 1 — 0.5–1
A90V 2–8 4 0.5–4 — 0.5–1
CDC1551 D94G 8 8 8 — 2
gyrB — N510D 120 — 500 45 35 Aubry et al.,
200629
— WT — 7 22 9 16 Kim et al.,
201136E540V — 251 82 37 61
— WT 10 — 8 3 2.5 Pantel et al.,
201237D500A 22 — 25 8 6
N538T 28 — 24 14 12
T539P 30 — 17 13 12
E540V 80 — 64 .20 .20
H37Rv or
Erdman
WT 0.5 ,0.25—0.5 ,0.25 — ,0.25—0.5 Malik et al.,
201231N538D 4 4 2 — 1
T539P 0.5–1 1 0.5–1 — 0.5–1
N538K 2 2 1 — 1–2
H37Rv E540V 4 2 1–2 — 0.5–1
D500H 4–8 1–2 2–4 — ,0.25–0.5
D500N 4 1 2 — ,0.25–0.5
N538D+T546M 2 4 2 — 1
N538T+T546M 0.5 2 0.5 — 0.5–1
A543V 2 1 1 — 0.5–1
E540D 0.5 0.5 0.5 — 2–4
R485C+T539N 4–8 2 2–4 — 2
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Beijing, which contains threonine at position 95, which may
already enhance resistance by altering interactions between
a4 and a3 helices.34,35
gyrB
MutationsthatcausedFQresistance Aubryetal.29 found that the
N510D mutation in gyrB led to an IC50 elevation (Table 4). Kim
et al.36 found that a gyrase bearing the E540Vamino acid substitu-
tion ingyrB, mimicking a clinical strain from Bangladesh, was highly
resistant to inhibition by four FQs. Pantel et al.37 reported that
D500A and N538T (located in the QRDR) and T539P (located
outside the QRDR) conferred low-level resistance, in contrast to
E540V (also outside the QRDR), which conferred higher-level resist-
ance. In contrast to the findings of Kim et al.36 and Pantel et al.,37
Malik et al.31 found that the resistance pattern of the E540V muta-
tion was dependent on the genetic background of the mutated
strain. In H37Rv, E540Vconferred consistent susceptibility to cipro-
floxacin but conferred resistance to levofloxacin and ofloxacin and
low-level resistance to moxifloxacin. In the Erdman background,
E540V exhibited cross-resistance to all four FQs tested during one
round of testing but was susceptible to moxifloxacin on repeat
testing. In addition, Malik et al.31 found that transformants har-
bouring D500A had increased MICs for levofloxacin and ofloxacin
(at least 4-fold), which were still considered in the susceptible
range; the MICs for ciprofloxacin and moxifloxacin were unaffected.
Malik et al.31 report that transformants harbouring gyrB D500H
or D500N were resistant to levofloxacin and ofloxacin but suscep-
tible to ciprofloxacin and moxifloxacin. The N538D-containing
transformant exhibited resistance to all four FQs. The N538D+T546M
double mutation conferred resistance to all of the FQs tested
when introduced into Erdman but did not significantly increase the
MIC to a greater extent than N538D alone. The N538D+T546M
double mutation resulted in slightly different results in the H37Rv
genetic background, where it was resistant to ciprofloxacin, levo-
floxacin and moxifloxacin but susceptible to ofloxacin. Transfor-
mants carrying another variant at codon 538, N538T, plus T546M
were susceptible to all FQs tested. These data suggest that T546M
does not play a synergistic role in FQ resistance and N538T does
not confer resistance. The R485Cand T539NgyrBmutations each in-
dependently increased the MIC, but not to clinical resistance levels.
The T539N mutation did confer low-level resistance to moxifloxacin
in the Erdman strain. When introduced together into H37Rv, gyrB
R485C+T539N conferred resistance to ofloxacin, levofloxacin and
moxifloxacin; the samedouble mutation in Erdman conferred resist-
ance to all four FQs tested. Based on these results, R485Cand T539N
individually increase the FQ MIC slightly but in combination they act
synergistically to increasethe MICabove the criticalconcentration to
confer clinical resistance.
Maliketal.31 found that the T539P mutation alone increased the
levofloxacin MIC, but not above the critical concentration; this mu-
tation did not substantially affect the MIC for any other FQ. Both
A543Tand A543V increased (2-fold to 4-fold) the MICs for levofloxa-
cin, ciprofloxacinandofloxacinbut had noeffect onthe moxifloxacin
MIC. These were still below the accepted critical concentration for
clinical resistance. The N538K mutation exhibited low-level resist-
ance to moxifloxacin and increased the MICs (4-fold) of ciprofloxa-
cin, ofloxacin and levofloxacin, although these increases were not
sufficient to be considered resistant.
Er
d
m
an
E5
4
0V
4
2
–
4
2
—
1
D
5
0
0H
4
–
8
1
2
–
4
—
0
.5
D
5
0
0N
4
2
2
—
0
.5
N
5
3
8D
+T
5
4
6
M
4
8
2
—
,
0
.2
5
–
1
N
5
3
8T
+
T5
4
6
M
0
.5
2
0
.5
—
,
0
.2
5
–
1
T5
3
9N
2
2
1
—
1
E5
4
0D
0
.5
–
1
0
.5
–
1
0
.5
—
2
R4
8
5C
+
T5
3
9
N
8
4
4
—
4
a
IC
5
0
s
w
er
e
d
et
er
m
in
ed
d
ire
ct
ly
on
re
co
m
bi
n
an
t
gy
rA
an
d
gy
rB
su
bu
n
it
s
pr
od
uc
ed
in
E.
co
li
pl
as
m
id
s.
A
ll
re
fe
re
n
ce
s
ex
ce
pt
fo
r
M
al
ik
et
al
.,3
1
u
se
d
IC
5
0
s.
b
Cr
it
ic
al
co
n
ce
n
tr
at
io
n
:M
IC
.
2
m
g/
L.
c C
rit
ic
al
co
n
ce
n
tr
at
io
n
:M
IC
.
2
m
g/
L.
d
Cr
it
ic
al
co
n
ce
n
tr
at
io
n
:M
IC
.
1
m
g/
L.
e
M
IC
.
0
.5
m
g/
L
(lo
w
-l
ev
el
re
si
st
an
ce
)a
n
d
.
2
m
g/
L
(h
ig
h
-l
ev
el
re
si
st
an
ce
).
Systematic review
9 of 12
JAC
Mutations that increased susceptibility or had no effect on FQ
resistance Pantel et al.38 studied eight substitutions in gyrB
(D473N, P478A, R485H, S486F, A506G, A547V, G551R and
G559A) and found that none of them was implicated in FQ resist-
ance (Table S1, available as Supplementary data at JAC Online).
Malik et al.31 found that gyrB M330I, V340L and T546M did not
confer resistance to any FQ tested. Transformants with D533A
were also susceptible to all four FQs. T546M did not confer FQ resist-
ance. Matrat et al.33 found that the R447K substitution conferred
increased susceptibility.
Discussion
In this systematic review we identified papers that introduced drug
resistance-conferring mutations into eight genes (katG, inhA, kasA,
embB, embC, rpoB, gyrA and gyrB) and one intergenic region (furA-
katG). Within these genomic regions, 25 individual mutations plus 3
double mutations caused clinical resistance to first-line drugs, and
8 resulted in no change in inhibitory concentration. A further 18 in-
dividual mutations and 7 double mutations caused clinical resist-
ance to one or more FQs, with 26 individual mutations and 4
double mutations conferring no change in FQ inhibitory concentra-
tions (Tables 2–4 and Table S1, available as Supplementary data at
JAC Online).
Several studies found that mutations can have a different effect
on the drug MIC, depending on the background strain intowhich it is
introduced. Forexample, the rpoBmutation Q513L led to high-level
resistance to rifampicin in strain KL463, lower-level resistance in
strain KL1936 and no significant increase in MIC in H37Ra. In
embB, mutation M306I (ATC) caused a moderately higher MIC in
strain 5310 compared with strain 210 and H37Rv. Similarly,
embB mutation M306I (ATA) resulted in varied levels of MIC:
7 mg/L in strain 210; 16 mg/L in strain 5310; 10 mg/L in a Beijing
F2 strain; and both 4 mg/L and 10 mg/L in two H37Rv-derived
strains in two different studies. Depending on what value is
chosen as the critical concentration cut-off, the latter H37Rv
could be considered ‘susceptible’ and the former ‘resistant’.9
Although all MICs consistently increased, such discrepancies
underline the limitations of the currently accepted critical concen-
tration cut-offs in determining clinical ‘resistance’, and suggest
that epistasis between the introduced mutations and other
genetic variation elsewhere in the genome plays an important
role in influencing the resistance phenotype. Mutation–mutation
interactions have been previously noted to influence the drug re-
sistance phenotype of other pathogens such as HIV.39 The obser-
vation of epistasis influencing the drug resistance phenotype in
Mtb challenges the reductionist view that one ‘correct’ mutation
is sufficient to result in resistance to a particular drug, and supports
the more comprehensive study of additional genes in the Mtb
genome that can modulate or contribute to the resistance pheno-
type in an alternative ‘multi-hit’ model.
This systematic review also demonstrates that the same drug
resistance mutations can cause varying levels of resistance to dif-
ferent members of the same drug class, For example, the D500H
mutation ingyrB led to resistance to earlier-generation FQs (ofloxa-
cin, levofloxacin) but not moxifloxacin. Likewise, clones containing
the D516V mutation in rpoB showed resistance to rifampicin and
rifapentine but maintained susceptibility to rifabutin. This finding
is consistent with similar observations made in clinical strains
that exhibited rifampicin resistance with rifabutin susceptibility
by current cut-offs.40
It is possible that these observations may be overemphasized
by the current, arguably arbitrary, drug concentration cut-offs for
clinical resistance. However, the observation that in isogenic back-
grounds the same mutation leads to smaller increments in MIC
for some members of the same drug class, coupled with the
known higher pharmacological potency of some of these agents
seems likely to have treatment implications. To date, there are no
directclinicalorpharmacologicaldatatosupporttheclinicalefficacy
of treating Mtb resistant to one member of the FQ or rifamycin drug
class with another member, but observations of improved treat-
ment outcomes for patients with extensively drug-resistant TB (by
definition resistant to a member of the FQ drug class) who were
treated with later-generation FQs (levofloxacin or moxifloxacin)
provide some indirect support for this notion.41–44 Evidence from
this review thus emphasizes the importance of further studying
FQs and alternative rifamycins to assess their clinical value in the
treatmentofMtbresistanttoothermembersof thesamedrugclass.
This systematic review highlights some notable lackof allelic ex-
change data for several of the genes known to be associated with
drug resistance. Notably, we found no studies that met our inclu-
sion criteria which studied pncA, rrs, inhA promoter region, or
ethAencoding resistance to the drugs pyrazinamide, streptomycin,
the aminoglycosides (amikacin, capreomycin, kanamycin) and
ethionamide. Even within the genes studied, only a subset of the
common mutations was studied in most cases. For example, we
found no report of allelic exchange experiments performed at
codon 91 of gyrA, or codons 446, 447, 461, 494, 501 and 504 of
gyrB, codons that have previously been associated with FQ resist-
ance in clinical strains.45,46
Rapid molecular assays for detecting drug resistance are cur-
rently limited, with GeneXpert (Cepheid) only testing for rifampicin
resistance, the sensitivity of the GenoType MTBDR test (Hain Life-
science) for the detection of isoniazid resistance reported to be in
the 80%–90% range47 – 49 and the GenoType MTBDRsl assay
showing a low level of performance for FQs, aminoglycosides and
ethambutol (reported sensitivities of 87%–89%, 21%–100%
and 39%–57%, respectively).50 – 53 Their accuracy is largely de-
pendent on the strength of the association between a specific mu-
tation and the resistance phenotype. These and further allelic
exchange studies may point towards recommendations for im-
proving the diagnostic accuracy of molecular-based resistance
assays, depending on their correlation with the frequency of
these mutations found in clinical strains. For example, including
embB mutations in codon 406, shown to increase the ethambutol
MICto aclinicallysignificant level in this review and also observed in
clinical isolates in India, Russia and the USA,54 – 56 could improve
the sensitivity for detecting resistance to ethambutol in those par-
ticular geographic settings. An updatable database on mutations
associated with resistance worldwide, such as TBDReaMDB, may
serve as a cross-check for the clinical relevance of including
newly identified mutations from allelic exchange studies into diag-
nostic tests.46 Finally, the reviewed allelic exchange experiments
suggest that mutation Q513L in rpoB, currentlyassayed in the Gen-
eXpert pipeline, does not result in aconsistent increase in rifampicin
MIC, depending on the strain background genome. This may have
an impact on GeneXpert’s specificity.
It is critical to note that drug susceptibility testing, although the
gold standard, is not 100% accurate. A lack of concordance with
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resistance screening may therefore not necessarily imply that re-
sistance has been missed. It has been shown that in vitro data do
not necessarily correlate with in vivo data and vice versa. For
example, mutations leading to only slightly raised in vitro rifampi-
cin resistance may indeed have clinical significance,57 while muta-
tions with dramatic in vitro effects may be unfit in vivo and hence
very rare in patient isolates.12 Whole genome sequencing and con-
vergence analysis may be particularly useful in identifying poten-
tial mutations of interest requiring confirmation.58,59
This systematic review highlights the current understanding of
the causal relationships of different mutations on phenotypic re-
sistance in Mtb as studied via allelic exchange. Given increasing
reports of Mtb strains with higher levels of drug resistance world-
wide, this review provides new suggestions for drug resistance
diagnostics development and highlights some gaps in our knowl-
edge of genotype–phenotype relationships that are worth
further study.
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